"On June 19, 2017, Lipocine Inc. issued a press release announcing topline results from the Dosing Validation study and the Dosing Flexibility study for LPCN 1021. The press release is filed as Exhibit 99.1 and is incorporated herein by reference."
"I could conduct another webinar on clinical trial red flags based solely on todays LPCN liver fat study press release. Missing patients (and too few overall), no placebo control, skewed means, arbitrary data cutoffs, etc etc. "
"Not that anyone trading cares, but today?s LPCN iver fat (NASH? NAFLD? Something else?) data are worse than the data previously disclosed in January. Also, wow, so many changes to endpoint definitions. Carry on?."